All Stories

  1. Effect of remdesivir on mortality and the need for mechanical ventilation among hospitalized patients with COVID-19: real-world data from a resource-limited country
  2. HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe
  3. Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps
  4. Causes and outcomes of hospitalizations among people living with HIV in Georgia’s referral institution, 2012–2017
  5. SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia
  6. Smoking and cessation-related attitudes among men who have sex with men in the country of Georgia
  7. HIV care in times of the COVID-19 crisis — Where are we now in Central and Eastern Europe?
  8. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons
  9. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting
  10. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia
  11. The EuroSIDA study: 25 years of scientific achievements
  12. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015–March 2018
  13. Impact of hepatitis C virus antibody positivity on mortality and causes of death in people living with HIV in Georgia
  14. Epidemiology of human immunodeficiency virus (HIV) drug resistance in HIV patients with virologic failure of first-line therapy in the country of Georgia
  15. Variation in antiretroviral treatment (ART) coverage and virological suppression among three HIV key populations
  16. The Attitudes, Needs, and Requirements at End of Life in the Republic of Georgia (Comparative Analysis of Groups of Patients With Cancer and Elders)
  17. Uptake of HCV treatment in HIV/HCV coinfected patients across europe in the era of direct-acting antivirals
  18. Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015
  19. Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era
  20. HIV Care in Central and Eastern Europe:How close are we to the target?
  21. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia
  22. Late presentation of HIV infection in the country of Georgia: 2012-2015
  23. Progress Toward Achieving the UNAIDS 90-90-90 Goals in HIV Care From Diagnosis to Durable Viral Suppression in the Country of Georgia
  24. Cascade of care among HIV patients diagnosed in 2013 in Georgia: Risk factors for late diagnosis and attrition from HIV care
  25. Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program
  26. National Progress Toward Hepatitis C Elimination — Georgia, 2015–2016
  27. Significant Improvements Are Needed in HIV Care Continuum to Meet 90-90-90 Targets in Georgia
  28. Assessment of quality of life in people living with HIV in Georgia
  29. Mismatch between physicians and family members views on communications about patients with chronic incurable diseases receiving care in critical and intensive care settings in Georgia: a quantitative observational survey
  30. The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia
  31. High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment
  32. The cascade of care in the Eastern European country of Georgia
  33. Mortality and Causes of Death Among HIV-Infected Individuals in the Country of Georgia: 1989–2012
  34. Estimating HIV incidence in eastern European country of Georgia: 2010–2012
  35. Evaluation of multiple measures of antiretroviral adherence in the Eastern European country of Georgia
  36. Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia
  37. Poor agreement between interferon-gamma release assays and the tuberculin skin test among HIV-infected individuals in the country of Georgia
  38. IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1
  39. Characterization of HIV‐1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia
  40. Outcomes of Universal Access to Antiretroviral Therapy (ART) in Georgia
  41. Characteristics of HIV-infected women and factors associated with HCV seropositivity in the Republic of Georgia